Anti-tumor activity of tigecycline: a review.

Erhu ZHAO; Xue WANG; Juanli JI; Zhongze WANG; Yi WANG; Hongjuan CUI

Return

Anti-tumor activity of tigecycline: a review.

Author: Erhu ZHAO ¹ ; Xue WANG ² ; Juanli JI ¹ ; Zhongze WANG ¹ ; Yi WANG ³ ; Hongjuan CUI ¹
Author Information

1. College of Sericulture, Textile and Biomass Sciences, State Key Laboratory of Silkworm Genome Biology, Southwest University, Chongqing 400716, China.
2. Chongqing General Hospital, University of Chinese Academy of Sciences, Chongqing 400014, China.
3. The No. 9 Hospital of Chongqing (The Affiliated Hospital of Southwest University), Chongqing 400700, China.
Publication Type:Review
Keywords: anti-tumor activity; clinical trial; drug combination; mitochondrial disorder; tigecycline
MeSH: Anti-Bacterial Agents/pharmacology*; Humans; Minocycline/pharmacology*; Mitochondria; Neoplasms/drug therapy*; Tigecycline/pharmacology*
From: Chinese Journal of Biotechnology 2021;37(9):3031-3041
CountryChina
Language:Chinese
Abstract: Tigecycline is a novel glycylcycline antibacterial drug, which shows both antibiotic function and anti-tumor activity. This review summarizes the single and combined use of tigecycline for tumor treatment and the underpinning mechanisms. As an inhibitor for mitochondrial DNA translation, tigecycline affects the proliferation, migration, and invasion of tumor cells mainly through inhibiting mitochondrial protein synthesis and inducing mitochondrial dysfunction. Although the effect of tigecycline monotherapy is controversial, the efficacy of combined use of tigecycline is satisfactory. Therefore, it is important to explore the molecular mechanisms underpinning the anti-tumor activity of tigecycline, with the aim to use it as a cheap and effective new anti-tumor drug.